Chardan Capital initiated coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $57.00 price target on the stock. MLTX has been the topic of a number of other reports. Wall Street Zen lowered shares of […]